Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor
The sphingosine-1-phosphate type 1 (S1P1) receptor is a new target in the treatment of auto-immune diseases as evidenced by the recent approval of FTY720 (Fingolimod).